Development of CAL101– a humanized monoclonal antibody targeting S100A4 to inhibit proinflammatory and profibrotic signaling in chronic fibrotic diseases - Signe Vedel Borchert

ELRIG Drug Discovery 2026 · 14 October 2026 · 15:45–16:15 · Exhibition Hall Theatre

Development of CAL101– a humanized monoclonal antibody targeting S100A4 to inhibit proinflammatory and profibrotic signaling in chronic fibrotic diseases - Signe Vedel Borchert was a session at ELRIG Drug Discovery 2026 on 14 October 2026 in London, with 1 speaker on record.

Speakers

• Signe Vedel Borchert — Speaker Preclinical Research Scientist, Calluna Pharma As